SEC Form SC 13D/A filed by Medpace Holdings Inc. (Amendment)

2/28/24 5:04:01 PM ET

$MEDP

Biotechnology: Commercial Physical & Biological Resarch

Health Care

Get the next $MEDP alert in real time by email

SC 13D/A 1 d757239dsc13da.htm SC 13D/A SC 13D/A

United States

Securities and Exchange Commission

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-101)

Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to

§ 240.13d-2(a)

Under the Securities Exchange Act of 1934

(Amendment No. 20)*

Medpace Holdings, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

58506Q109

(CUSIP Number)

August J. Troendle

c/o Medpace Holdings, Inc.

5375 Medpace Way

Cincinnati, OH 45227

Tel: (513) 579-9911

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

February 26, 2024

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


1	NAMES OF REPORTING PERSONS August J. Troendle
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☒
3	SEC USE ONLY
4	SOURCE OF FUNDS PF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER 806,643
		8	SHARED VOTING POWER 5,183,019
		9	SOLE DISPOSITIVE POWER 806,643
		10	SHARED DISPOSITIVE POWER 5,183,019
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,496,852
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 20.8%
14	TYPE OF REPORTING PERSON IN


1	NAMES OF REPORTING PERSONS Medpace Investors, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☒
3	SEC USE ONLY
4	SOURCE OF FUNDS OO
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER 0
		8	SHARED VOTING POWER 5,183,019
		9	SOLE DISPOSITIVE POWER 0
		10	SHARED DISPOSITIVE POWER 5,183,019
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,183,019
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 16.6%
14	TYPE OF REPORTING PERSON OO (Limited liability company)

This Amendment No. 20 to the Schedule 13D (this “Amendment No. 20”) amends and supplements the Statement on Schedule 13D filed with the United States Securities and Exchange Commission on August 26, 2016, as amended by Amendment No. 1 filed on August 8, 2018, Amendment No. 2 filed on October 2, 2018, Amendment No. 3 filed on February 6, 2019, Amendment No. 4 filed on August 5, 2019, Amendment No. 5 filed on August 7, 2019, Amendment No. 6 filed on August 15, 2019, Amendment No. 7 filed on September 17, 2019, Amendment No. 8 filed on May 8, 2020, Amendment No. 9 filed on July 31, 2020, Amendment No. 10 filed on August 14, 2020, Amendment No. 11 filed on December 21, 2020, Amendment No. 12 filed on April 21, 2021, Amendment No. 13 filed on September 1, 2021, Amendment No. 14 filed on December 23, 2021, Amendment No. 15 filed on July 6, 2022, Amendment No. 16 filed on September 13, 2022, Amendment No. 17 filed September 21, 2022, Amendment No. 18 filed September 22, 2023, and Amendment No. 19 filed December 5, 2023 (collectively, the “Statement”), relating to the common stock (the “Common Stock”), of Medpace Holdings, Inc., a Delaware corporation (the “Issuer”). Capitalized terms used herein without definition shall have the meaning set forth in the Statement.

Item 5. Interest in Securities of the Issuer

Items 5(a) - (b) of the Statement are amended and restated in their entirety as follows: (a) - (b): See Items 7 – 13 of the cover pages above.

Item 5(c) of the Statement is amended and supplemented by inserting the following information:

(c): Medpace Investors, LLC (“MPI”) has sold shares in open market transactions executed pursuant to limit orders between February 16, 2024 and February 27, 2024 as follows:


Trade Date	Shares Sold		Price Per Share
02/16/2024		15,742	$	390.81	⁽¹⁾
02/16/2024		21,586	$	391.42	⁽²⁾
02/16/2024		5,794	$	392.48	⁽³⁾
02/16/2024		1,757	$	393.76	⁽⁴⁾
02/16/2024		5,121	$	394.49	⁽⁵⁾
02/20/2024		6,136	$	385.27	⁽⁶⁾
02/20/2024		3,268	$	386.21	⁽⁷⁾
02/20/2024		2,624	$	387.60	⁽⁸⁾
02/20/2024		1,859	$	388.52	⁽⁹⁾
02/20/2024		101	$	389.12	⁽¹⁰⁾
02/21/2024		3,199	$	380.54	⁽¹¹⁾
02/21/2024		4,058	$	381.38	⁽¹²⁾
02/21/2024		6,724	$	382.52	⁽¹³⁾
02/21/2024		10,147	$	383.44	⁽¹⁴⁾
02/21/2024		3,691	$	384.51	⁽¹⁵⁾
02/21/2024		3,110	$	385.44	⁽¹⁶⁾
02/21/2024		5,083	$	386.18	⁽¹⁷⁾
02/22/2024		1,540	$	391.40	⁽¹⁸⁾
02/22/2024		1,611	$	392.35	⁽¹⁹⁾
02/22/2024		21,028	$	393.39	⁽²⁰⁾
02/22/2024		17,672	$	394.41	⁽²¹⁾
02/22/2024		14,578	$	395.17	⁽²²⁾
02/22/2024		5,806	$	396.49	⁽²³⁾
02/22/2024		4,819	$	397.36	⁽²⁴⁾
02/22/2024		17,676	$	398.27	⁽²⁵⁾
02/22/2024		9,666	$	399.29	⁽²⁶⁾
02/22/2024		4,873	$	400.28	⁽²⁷⁾
02/22/2024		731	$	401.28	⁽²⁸⁾
02/23/2024		452	$	396.77	⁽²⁹⁾
02/23/2024		1,883	$	397.88	⁽³⁰⁾
02/23/2024		7,273	$	398.75	⁽³¹⁾
02/23/2024		39,444	$	399.79	⁽³²⁾
02/23/2024		31,718	$	400.57	⁽³³⁾
02/23/2024		15,784	$	401.81	⁽³⁴⁾
02/23/2024		3,446	$	402.25	⁽³⁵⁾
02/26/2024		76	$	397.98
02/26/2024		436	$	399.26	⁽³⁶⁾
02/26/2024		798	$	400.81	⁽³⁷⁾
02/26/2024		22,033	$	401.59	⁽³⁸⁾
02/26/2024		21,845	$	402.57	⁽³⁹⁾
02/26/2024		8,653	$	403.42	⁽⁴⁰⁾


02/26/2024	1,755	$	404.44	⁽⁴¹⁾
02/26/2024	1,332	$	405.14	⁽⁴²⁾
02/27/2024	3,354	$	399.37	⁽⁴³⁾
02/27/2024	8,585	$	400.45	⁽⁴⁴⁾
02/27/2024	10,682	$	401.25	⁽⁴⁵⁾
02/27/2024	12,988	$	402.29	⁽⁴⁶⁾
02/27/2024	13,349	$	403.38	⁽⁴⁷⁾
02/27/2024	1,042	$	404.01	⁽⁴⁸⁾

(1)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $390.06 to $391.05. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(2)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $391.06 to $392.05. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(3)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $392.06 to $393.02. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(4)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $393.12 to $394.04. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(5)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $394.06 to $394.95. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(6)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $385.00 to $385.90. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(7)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $386.05 to $386.59. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(8)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $387.06 to $387.97. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(9)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $388.00 to $388.85. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(10)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $389.03 to $389.34. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(11)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $379.96 to $380.94. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(12)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $380.96 to $381.87. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(13)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $381.96 to $382.93. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(14)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $382.98 to $383.95. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(15)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $383.97 to $384.88. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(16)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $384.985 to $385.95. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(17)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $385.98 to $386.56. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(18)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $390.86 to $391.84. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(19)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $391.87 to $392.76. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(20)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $392.86 to $393.81. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(21)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $393.885 to $394.85. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(22)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $394.855 to $395.82. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(23)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $395.86 to $396.83. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(24)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $396.86 to $397.85. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(25)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $397.86 to $398.85. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(26)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $398.90 to $399.78. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(27)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $399.86 to $400.755. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(28)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $400.97 to $401.45 The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(29)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $396.15 to $397.03. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(30)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $397.29 to $398.14. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(31)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $398.15 to $399.14. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(32)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $399.15 to $400.145. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(33)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $400.15 to $401.145. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(34)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $401.18 to $402.14. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(35)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $402.15 to $402.50. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(36)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $399.05 to $400.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(37)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $400.64 to $400.98. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(38)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $401.02 to $401.97. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(39)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $401.98 to $402.975. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(40)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $402.98 to $403.95. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(41)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $403.98 to $404.92. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(42)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $405.00 to $405.72. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(43)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $398.84 to $399.82. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(44)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $399.85 to $400.83. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(45)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $400.84 to $401.80. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(46)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $401.85 to $402.825. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(47)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $402.84 to $403.78. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(48)

The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $403.91 to $404.17. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

Item 7. Materials to be Filed as Exhibits


Exhibit Number		Description

1		Joint Filing Agreement*

2		Registration Rights Agreement*

*	Filed in the Statement.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 28, 2024

/s/ August J. Troendle

August J. Troendle

Medpace Investors, LLC

/s/ August J. Troendle

Name: August J. Troendle

Title: Sole Manager

Get the next $MEDP alert in real time by email

Date	Price Target	Rating	Analyst
10/23/2024	$413.00 → $349.00	Outperform → Neutral	Robert W. Baird
10/14/2024		Buy	Redburn Atlantic
9/27/2024	$420.00 → $350.00	Buy → Neutral	UBS
9/25/2024	$415.00 → $345.00	Buy → Hold	Jefferies
8/1/2024	$415.00	Hold	Truist
5/29/2024	$452.00	Buy	TD Cowen
5/28/2024	$435.00	Buy	Mizuho
4/23/2024	$340.00 → $450.00	Hold → Buy	Jefferies

SEC Form SC 13D/A filed by Medpace Holdings Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for
$MEDP

$MEDP
Financials

Live finance-specific insights

Medpace Holdings, Inc. Reports Third Quarter 2024 Results

Medpace Holdings, Inc. to Report Third Quarter 2024 Financial Results on October 21, 2024

Medpace Holdings, Inc. Reports Second Quarter 2024 Results

$MEDP
Press Releases

Fastest customizable press release news feed in the world

Medpace Holdings, Inc. Reports Third Quarter 2024 Results

Medpace Holdings, Inc. to Report Third Quarter 2024 Financial Results on October 21, 2024

Berry and Glatfelter Announce Magnera Board of Director Appointments in Connection With Proposed Merger of Berry's Health, Hygiene and Specialties Global Nonwovens and Films Business With Glatfelter

$MEDP
SEC Filings

SEC Form 10-Q filed by Medpace Holdings Inc.

Medpace Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Amendment: SEC Form 144/A filed by Medpace Holdings Inc.

$MEDP
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Medpace downgraded by Robert W. Baird with a new price target

Redburn Atlantic initiated coverage on Medpace

Medpace downgraded by UBS with a new price target

$MEDP
Market Insights

Live Market Insights

Medpace Holdings shares are trading higher after falling on Tuesday following Q2 earnings.

Baird Maintains Outperform on Medpace Hldgs, Lowers Price Target to $430

Deutsche Bank Maintains Hold on Medpace Hldgs, Lowers Price Target to $336

$MEDP
Leadership Updates

Live Leadership Updates

$MEDP
Large Ownership Changes

This live feed shows all institutional transactions in real time.

$MEDP
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Medpace Holdings, Inc. Announces Senior Leadership Changes